Education
About Us
Working with TipRanks
Follow Us
Champions Oncology Inc (CSBR)
NASDAQ:CSBR
CSBR Stock Chart & Stats
$6.64
-$0.91(-8.67%)
At close: 4:00 PM EST
$6.64
-$0.91(-8.67%)
Day’s Range― - ―
52-Week Range$5.50 - $10.17
Previous CloseN/A
Volume27.06K
Average Volume (3M)17.98K
Market Cap
$81.38M
Enterprise Value$79.25M
Total Cash (Recent Filing)$7.13M
Total Debt (Recent Filing)$5.00M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Jul 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding13,886,826
10 Day Avg. Volume35,034
30 Day Avg. Volume17,980
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)25.89
Price to Sales (P/S)1.72
P/FCF Ratio13.96
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue1.37
Enterprise Value/Gross Profit3.15
Enterprise Value/Ebitda-88.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.12
Revenue Forecast (FY)$58.53M
Bulls Say, Bears Say
Bulls Say
Services (Core Study) Revenue GrowthSustained growth in core services demonstrates durable demand and execution in the firm's primary business. A record quarter of study revenue signals expanding customer adoption and backlog conversion, supporting predictable contracted services revenue over the next several quarters.
Positive Adjusted EBITDA Momentum & Cash GenerationConsistent adjusted EBITDA gains and positive TTM cash flow indicate the business can generate cash despite GAAP swings. This improves financial resilience, funds organic investments, and reduces near-term refinancing risk, supporting stability across the next 2-6 months.
Manageable Leverage And LiquidityA cash balance with no debt and historically manageable leverage gives the company flexibility to fund operations and strategic investments without immediate capital markets dependence. That balance-sheet position buffers short-term volatility and supports execution of growth projects.
Bears Say
Revenue Decline & Lumpy RecognitionTop-line volatility and a steep TTM decline highlight structural sensitivity to timing and recognition of data deals. Reliance on episodic data license revenue makes multi-period revenue visibility weak and complicates stable margin expansion over the medium term.
Gross Margin Compression From Outsourced CostsMaterial margin contraction tied to outsourced lab costs undermines sustainable profitability. If outsourcing remains necessary, gross margins may stay depressed; reversing this requires internalizing costly capabilities or securing better cost terms, which takes quarters to execute.
Nascent Data Business & Uncertain Corellia FundingThe data platform's early-stage, lumpy revenue profile and unclear external financing for Corellia create execution risk. Continued internal funding of Corellia could suppress corporate EBITDA and cash flow until external financing or licensing crystallizes, weighing on near-term durability.
Champions Oncology News
CSBR FAQ
What was Champions Oncology Inc’s price range in the past 12 months?
Champions Oncology Inc lowest stock price was $5.50 and its highest was $10.17 in the past 12 months.
What is Champions Oncology Inc’s market cap?
Champions Oncology Inc’s market cap is $81.38M.
When is Champions Oncology Inc’s upcoming earnings report date?
Champions Oncology Inc’s upcoming earnings report date is Jul 16, 2026 which is in 115 days.
How were Champions Oncology Inc’s earnings last quarter?
Champions Oncology Inc released its earnings results on Mar 12, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by -$0.11.
Is Champions Oncology Inc overvalued?
According to Wall Street analysts Champions Oncology Inc’s price is currently Overvalued.
Does Champions Oncology Inc pay dividends?
Champions Oncology Inc does not currently pay dividends.
What is Champions Oncology Inc’s EPS estimate?
Champions Oncology Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Champions Oncology Inc have?
Champions Oncology Inc has 13,886,826 shares outstanding.
What happened to Champions Oncology Inc’s price movement after its last earnings report?
Champions Oncology Inc reported an EPS of -$0.02 in its last earnings report, missing expectations of $0.09. Following the earnings report the stock price went up 6.272%.
Which hedge fund is a major shareholder of Champions Oncology Inc?
Currently, no hedge funds are holding shares in CSBR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Champions Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
CSBR Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.39%
12-Months-Change
Fundamentals
Return on Equity
-57.20%
Trailing 12-Months
Asset Growth
-7.12%
Trailing 12-Months
Company Description
Champions Oncology Inc
Champions Oncology (CSBR) is a biotechnology company that specializes in personalized medicine, particularly in the field of oncology. The company develops advanced technology platforms, including its proprietary TumorGraft® technology, which allows for the creation of patient-derived tumor models for use in drug development and treatment selection. By providing solutions that enhance the understanding of cancer biology and treatment responses, Champions Oncology serves pharmaceutical companies, academic institutions, and healthcare providers globally.
CSBR Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid operational execution — record services revenue, ~32% growth in core study revenue, and a third consecutive positive adjusted EBITDA — alongside deliberate investments in data and a therapeutic subsidiary (Corellia). However, near-term challenges include a modest overall revenue decline (~3%) driven by absence of prior-year data license revenue, compression of gross margin (61% to 47%) driven in part by outsourced radiolabeling costs, and elevated operating expenses (~+36%). Data revenue remains early and variable, and Corellia funding timing is uncertain. On balance, the positive operational momentum and pathway to monetize data and Corellia slightly outweigh the near-term margin and timing headwinds.View all CSBR earnings summariesTechnical Analysis
Ownership Overview
14.82% Insiders
3.06% Mutual Funds
32.87% Other Institutional Investors
46.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---